Better Coronavirus Stock: Gilead Sciences vs. Moderna
When the history books are written about the COVID-19 pandemic, two biotechs will almost certainly be included. Gilead Sciences (NASDAQ: GILD) became the first company to win emergency use authorization from the Food and Drug Administration for a new drug for treating COVID-19, remdesivir (which is marketed under the brand name Veklury). Moderna (NASDAQ: MRNA) ranks as one of the leaders in the race to develop a coronavirus vaccine.
So far this year, Moderna has been by far the bigger winner in terms of stock performance. Its shares have soared more than 240%, while Gilead's shares are down year to date. But which of these coronavirus-focused stocks is the better pick for long-term investors?
Image source: Getty Images.
Source Fool.com
